Devyser Diagnostics Investor Relations Material
Latest events
Q2 2024
Devyser Diagnostics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Devyser Diagnostics
Access all reports
Devyser Diagnostics AB provides diagnostic kits for DNA testing within hereditary diseases, oncology, and transplantation. The company offers products in the areas of transplantation, thalassemia, oncology, fetal RHD screening non-invasive prenatal testing, hereditary, cystic fibrosis, cardiovascular and male infertility testing, as well as rapid aneuploidy analysis. Its products are used to guide targeted cancer therapies; enable rapid prenatal diagnostics; and in post-transplant follow-up.
Key slides for Devyser Diagnostics
Q3 2023
Devyser Diagnostics
Q1 2024
Devyser Diagnostics
Latest articles
Qualcomm: Quality Communication and Semiconductor Innovation
Founded in 1985, Qualcomm has transformed the digital communication industry with CDMA technology and its advanced semiconductor business.
13 Sep 2024
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
Ticker symbol
DVYSR
Country
🇸🇪 Sweden